Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease

[1]  J. Clemmer,et al.  Endothelin antagonism reduces hemoglobin A1c in patients with pulmonary hypertension. , 2022, Canadian Journal of Physiology and Pharmacology.

[2]  S. Kwak,et al.  Association of Longitudinal Trajectories of Insulin Resistance With Adverse Renal Outcomes. , 2022, Diabetes care.

[3]  J. McMurray,et al.  Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial , 2020, Diabetes, obesity & metabolism.

[4]  D. De Martini.  Empowering phase II clinical trials to reduce phase III failures , 2019, Pharmaceutical statistics.

[5]  Debra F. Weinstein,et al.  Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. , 2019, Lancet.

[6]  L. Groop,et al.  Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. , 2018, The lancet. Diabetes & endocrinology.

[7]  J. McMurray,et al.  Baseline characteristics and enrichment results from the SONAR trial , 2018, Diabetes, obesity & metabolism.

[8]  J. McMurray,et al.  Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy , 2018, Diabetes, obesity & metabolism.

[9]  Bo Wang,et al.  Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. , 2016, JAMA internal medicine.

[10]  H. Parving,et al.  The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[11]  B. Howard,et al.  Insulin Resistance, Incident Cardiovascular Diseases, and Decreased Kidney Function Among Nondiabetic American Indians , 2013, Diabetes Care.

[12]  D. Kohan,et al.  Endothelin antagonists for diabetic and non‐diabetic chronic kidney disease , 2012, British journal of clinical pharmacology.

[13]  C. Yen,et al.  Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  P. Nilsson,et al.  Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes , 2007, Journal of Human Hypertension.

[15]  G. Bakris,et al.  Review: Insulin and endothelin: an interplay contributing to hypertension development? , 2007, The Journal of clinical endocrinology and metabolism.

[16]  B. Dimitrov,et al.  Insulin Resistance and Microalbuminuria , 2006, Diabetes.

[17]  P. Whelton,et al.  Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. , 2003, Journal of the American Society of Nephrology : JASN.

[18]  E. Gabazza,et al.  Neither homeostasis model assessment nor quantitative insulin sensitivity check index can predict insulin resistance in elderly patients with poorly controlled type 2 diabetes mellitus. , 2002, The Journal of clinical endocrinology and metabolism.

[19]  M. White,et al.  Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. , 1999, Diabetes.

[20]  C. Juan,et al.  Evidence that endothelin-1 (ET-1) inhibits insulin-stimulated glucose uptake in rat adipocytes mainly through ETA receptors. , 1998, Metabolism: clinical and experimental.

[21]  G. Ahlborg,et al.  Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. , 1997, Acta physiologica Scandinavica.

[22]  L. Monti,et al.  Hypertriglyceridemia and Hyperinsulinemia Are Potent Inducers of Endothelin-1 Release in Humans , 1996, Diabetes.

[23]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[24]  Paul Cahasan.  Copenhagen, Denmark , 2019, The Statesman’s Yearbook Companion.

[25]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[26]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.